Search research articles
Contact Us
Filters
Showing results (151-160 of 173) with videos related to
Page
of 18
Sort By:
Leukemia & Lymphoma
|
February 1, 1997
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
A Engert, R Schnell, F Küpper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2006
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
B Klimm, H T Eich, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2005
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
L Nogová, T Reineke, H T Eich, et al.
Nuklearmedizin. Nuclear Medicine
|
September 22, 2015
Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma
C Kobe, G Kuhnert, H Haverkamp, et al.
Blood
|
January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
A Engert, V Diehl, R Schnell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma
S Sasse, B Klimm, H Görgen, et al.
Leukemia
|
April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
A Josting, C Rudolph, M Mapara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
V Ballova, J-U Rüffer, H Haverkamp, et al.
Leukemia
|
November 6, 2009
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species
A M Vahdat, K S Reiners, V L Simhadri, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 173) with videos related to
Sort By:
Page
of 18
Leukemia & Lymphoma
|
February 1, 1997
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
A Engert, R Schnell, F Küpper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2006
Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group
B Klimm, H T Eich, H Haverkamp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 12, 2005
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)
L Nogová, T Reineke, H T Eich, et al.
Nuklearmedizin. Nuclear Medicine
|
September 22, 2015
Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphoma
C Kobe, G Kuhnert, H Haverkamp, et al.
Blood
|
January 15, 1997
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma
A Engert, V Diehl, R Schnell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 7, 2012
Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma
S Sasse, B Klimm, H Görgen, et al.
Leukemia
|
April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
A Josting, C Rudolph, M Mapara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 16, 2004
A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)
V Ballova, J-U Rüffer, H Haverkamp, et al.
Leukemia
|
November 6, 2009
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species
A M Vahdat, K S Reiners, V L Simhadri, et al.
Page
of 18